Mehdi A, Attias M, Arakelian A, Piccirillo C, Szyf M, Rabbani S. Co-Targeting Luminal B Breast Cancer with S-Adenosylmethionine and Immune Checkpoint Inhibitor Reduces Primary Tumor Growth and Progression, and Metastasis to Lungs and Bone. Cancers (Basel). 2022;15: pubmed publisher

Edwards C, Sette A, Cox C, Di Fiore B, Wyre C, Sydoruk D, et al. The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity. Br J Cancer. 2021;: pubmed publisher

Guiteras J, de Ramon L, Crespo E, Bolaños N, Barceló Batllori S, Martinez Valenzuela L, et al. Dual and Opposite Costimulatory Targeting with a Novel Human Fusion Recombinant Protein Effectively Prevents Renal Warm Ischemia Reperfusion Injury and Allograft Rejection in Murine Models. Int J Mol Sci. 2021;22: pubmed publisher

Silva Pilipich N, Martisova E, Ballesteros Briones M, Hervas Stubbs S, Casares N, Gonzalez Sapienza G, et al. Long-Term Systemic Expression of a Novel PD-1 Blocking Nanobody from an AAV Vector Provides Antitumor Activity without Toxicity. Biomedicines. 2020;8: pubmed publisher

Jacobs L, De Smidt E, Geukens N, Declerck P, Hollevoet K. DNA-Based Delivery of Checkpoint Inhibitors in Muscle and Tumor Enables Long-Term Responses with Distinct Exposure. Mol Ther. 2020;28:1068-1077 pubmed publisher

Matsumura T, Sugawara Y, Yutani M, Amatsu S, Yagita H, Kohda T, et al. Botulinum toxin A complex exploits intestinal M cells to enter the host and exert neurotoxicity. Nat Commun. 2015;6:6255 pubmed publisher

Butte M, Keir M, Phamduy T, Sharpe A, Freeman G. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27:111-22 pubmed

Arnett H, Escobar S, Gonzalez Suarez E, Budelsky A, Steffen L, Boiani N, et al. BTNL2, a butyrophilin/B7-like molecule, is a negative costimulatory molecule modulated in intestinal inflammation. J Immunol. 2007;178:1523-33 pubmed